Answers are grounded in this paper and cite their sources.
A large variety of new assays are available to test for antibodies to hepatitis C virus. We investigated the concordance of two FDA-licensed screening assays and determined their specificities in relation to two supplemental tests, Abbott’s neutralization assay and Ortho’s second generation RIBA-2. Of 573 serum samples from individuals at high risk for sexually transmitted diseases, 81 (14.1%) were repeatedly reactive by both screening tests and produced positive results by both supplemental assays, while 480 (83.8%) samples were nonreactive. Ten of the positive samples were reactive by the RIBA-2 assay to at least two antigens other than cl00-3, and were neutralized (88% to 100%) by Abbott’s supplemental assay. Twelve samples produced discrepant results, including one false-negative and 10 false-positive screening test results.
No takes yet. Share an insight, caveat, or question.
Constantine et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: